Survodutide is a synthetic peptide designed to act as a dual agonist at the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. This investigational molecule belongs to a class of peptides engineered to probe metabolic pathways by simultaneously engaging both receptor systems. By combining structural elements that interact with these G-protein-coupled receptors, survodutide offers a tool for researchers investigating energy homeostasis, nutrient sensing, and glucose regulation.<\/p>\n
This product is supplied as a lyophilized bulk powder, intended exclusively for laboratory research use. It is not formulated as a pharmaceutical medication and must never be administered to humans or animals outside of approved experimental protocols under institutional oversight. The material is not sterile for clinical applications and should be handled as a research chemical with appropriate precautions. Any reference to its biological activity is strictly in the context of controlled in vitro or in vivo laboratory studies.<\/p>\n
The availability of survodutide in bulk powder form allows research institutions, pharmaceutical R&D laboratories, and authorized distributors to obtain larger quantities for systematic investigation, assay development, or receptor screening programs. Each batch is synthesized under controlled conditions, and the bulk presentation minimizes the need for frequent reordering in long-term projects.<\/p>\n
Survodutide is a 29-amino acid peptide with a molecular formula of C\u2081\u2085\u2082H\u2082\u2082\u2088N\u2084\u2080O\u2084\u2085 and a molecular weight of approximately 3232.6 g\/mol. Its primary sequence has been modified to include non-standard residues and structural features that enhance binding affinity and metabolic stability. The C-terminus is present as an amide, while the N-terminal region includes an extension that influences receptor selectivity.<\/p>\n
The peptide chain incorporates specific amino acid substitutions that confer resistance to rapid enzymatic degradation, a common challenge in research with native GLP-1. These modifications prolong the half-life in biological matrices without altering the fundamental receptor interaction domains. The sequence design is based on insights from structure-activity relationship studies of incretin and glucagon receptor agonists, allowing survodutide to balance activation of both targets with measurable potency differences that can be probed experimentally.<\/p>\n
In its lyophilized state, survodutide appears as a white to off-white amorphous powder. It is soluble in water and common aqueous buffers, though solubility characteristics may vary with pH and ionic strength. The peptide’s secondary structure in solution, stabilized by intramolecular interactions, influences its receptor engagement profile. Researchers often verify structural integrity by mass spectrometry and high-performance liquid chromatography after reconstitution, especially in long-term studies where aggregation or degradation could confound results.<\/p>\n
Survodutide bulk powder serves as a key reagent in research programs exploring the integrated control of metabolism through combined GLP-1 and glucagon receptor activation. The dual agonism profile makes it a valuable molecular probe for dissecting the contributions of each signaling pathway to outcomes observed in cellular and animal models. Typical applications span from receptor pharmacology assays to whole-body energy balance studies in rodents, always within an experimental framework that does not involve human subjects.<\/p>\n
Investigators use survodutide to generate data on receptor binding kinetics, intracellular second messenger responses, and tissue-specific gene expression changes. The compound is also employed in comparative studies against single-receptor agonists to delineate synergistic or additive effects. Because bulk powder can be precisely weighed and aliquoted, it supports dose-ranging experiments and the preparation of stock solutions at defined concentrations for reproducible protocols.<\/p>\n
In vitro experiments commonly utilize immortalized cell lines that stably or transiently express recombinant human GLP-1 and glucagon receptors. These models allow for the assessment of survodutide\u2019s receptor activation profile through functional assays such as cyclic AMP (cAMP) accumulation measurements. By treating cells with a range of concentrations, researchers construct dose-response curves to calculate half-maximal effective concentrations and compare selectivity ratios between the two receptor subtypes.<\/p>\n
Beyond simple binding and activation, mechanistic studies focus on downstream intracellular signaling cascades. For example, survodutide\u2019s effect on insulin-secreting cell lines can be examined by measuring glucose-stimulated insulin release under controlled conditions, without implying any therapeutic relevance. Parallel investigations into gluconeogenic gene expression in hepatocyte models help clarify how dual receptor engagement modulates cellular metabolic programs. Western blotting, luciferase reporter assays, and phosphoproteomics are frequently paired with survodutide treatment to map pathway activation.<\/p>\n
Rodent models are instrumental for exploring the biological impact of survodutide in a whole-organism context. Diet-induced obesity (DIO) models in mice or rats receive the peptide via subcutaneous or intraperitoneal injection, after which food intake, body weight trajectory, and body composition are monitored longitudinally. These studies generate data on energy intake and expenditure, offering insights into the interplay between GLP-1 and glucagon receptor signaling without any clinical endpoint.<\/p>\n
Glucose homeostasis is another key outcome measure, typically assessed through oral or intraperitoneal glucose tolerance tests. Insulin sensitivity can be quantified using insulin tolerance tests or hyperinsulinemic-euglycemic clamps, providing information on how survodutide influences systemic metabolic handling. Pharmacokinetic profiling\u2014determining plasma half-life, maximum concentration, and bioavailability\u2014is performed by serial blood sampling and subsequent analysis via liquid chromatography-tandem mass spectrometry. These data help researchers design optimal dosing schedules for their experimental protocols and compare the compound\u2019s behavior with that of native peptides or other modified analogues.<\/p>\n
Survodutide bulk powder is manufactured to meet stringent quality specifications suitable for research use. Purity is verified by reverse-phase high-performance liquid chromatography (HPLC) and is guaranteed to be at least 95%. This level ensures that the primary peptide constitutes the overwhelming majority of the material, minimizing interference from related impurities in sensitive assays.<\/p>\n
Peptide content, which accounts for the actual mass of the peptide moiety counterions, water, or residual solvents, is determined by amino acid analysis. This quantitative method provides an accurate measure of the active peptide present per unit mass of lyophilized powder, critical for precise molar calculations in solution. Identity is confirmed using electrospray ionization mass spectrometry, matching the observed molecular ion to the theoretical value within an acceptable mass window. Additionally, endotoxin levels are controlled to less than 1 EU\/mg, measured by the Limulus amebocyte lysate test, to render the material compatible with in vivo studies where low endotoxin loads are required to prevent nonspecific immune responses.<\/p>\n
Proper storage is essential to maintain the long-term stability of survodutide bulk powder. Upon receipt, the lyophilized product should be stored at -20\u00b0C in a desiccated, light-protected environment. Exposure to moisture or temperature fluctuations can promote aggregation or chemical degradation, so containers should be tightly sealed and allowed to reach room temperature before opening to avoid condensation.<\/p>\n
For reconstitution, sterile distilled water or an appropriate buffer, such as phosphate-buffered saline, is recommended. The solution should be prepared immediately before the planned experiment, as dissolved peptides are more susceptible to hydrolysis and oxidation. If multiple experiments are anticipated, the reconstituted solution can be aliquoted into single-use portions and stored frozen, but repeated freeze-thaw cycles must be avoided. Researchers should consult the Certificate of Analysis for any batch-specific solubility notes and perform visual inspection for clarity after resuspension.<\/p>\n
Survodutide bulk powder is classified as a research chemical and is designated for laboratory use only under the supervision of qualified scientists. It is not intended for any clinical diagnostic procedure, nor for administration to humans or animals outside of approved experimental settings. Institutions are responsible for ensuring that all work with this compound complies with local, national, and international regulations governing chemical use and animal research.<\/p>\n
During handling, appropriate personal protective equipment\u2014including gloves, safety goggles, and a laboratory coat\u2014should be worn to prevent skin or eye contact. All manipulations should be conducted in a designated area with adequate engineering controls, such as a fume hood if weighing dry powder. Waste disposal must align with institutional biosafety and chemical hygiene plans; contaminated materials and unused solutions should be treated as potentially hazardous and disposed of according to established protocols.<\/p>\n
Researchers and procurement officers can obtain survodutide bulk powder in standard sizes of 10 mg, 50 mg, and 100 mg. For studies requiring larger amounts, custom bulk quantities can often be accommodated upon request. Each order is supplied with a unique batch number and a printed Certificate of Analysis (CoA) that reports HPLC purity, mass spectrometry identity confirmation, and endotoxin levels, enabling traceability and quality assurance.<\/p>\n
Typical lead time for standard orders is 3 to 5 business days from confirmation, though this may vary based on inventory levels and destination. Shipping is coordinated to maintain cold-chain conditions when necessary, and the product is packaged in sealed vials under an inert atmosphere to preserve integrity. For international shipments, the purchaser must confirm that import of this research material is permitted under local regulations and assumes responsibility for any duties or customs requirements.<\/p>\n
Nota: Solo para uso en investigaci\u00f3n:<\/strong> Survodutide bulk powder is furnished strictly for in vitro and in vivo laboratory research. It is not a pharmaceutical agent and must not be used for any purpose involving human or veterinary subjects, clinical applications, or medical procedures. Any experimental use must follow all applicable institutional, national, and international guidelines.<\/p>\n Solo para uso en investigaci\u00f3n. No apto para uso humano ni veterinario.<\/em><\/p>","protected":false},"excerpt":{"rendered":" Introduction to Survodutide Bulk Powder for Research Survodutide is a synthetic peptide designed to act as a dual agonist at the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. This investigational molecule belongs to a class of peptides engineered to probe metabolic pathways by simultaneously engaging both receptor systems. By combining structural elements that interact […]<\/p>\n","protected":false},"author":1,"featured_media":2053,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"news_category":[],"class_list":["post-2052","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\n